While the meta-analysis demonstrated good overall accuracy, the limitations and variations in the included studies highlight the need for additional clinical trials and real-world data to validate the use of urinary CCL14 as a biomarker for predicting persistent AKI. The gene discussed is CCL14; the disease is acute kidney injury.